We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
There is an urgent need for new drugs to combat tuberculosis (TB), as the disease spreads and the incidence of extremely drug-resistant TB (XDR-TB) continues to rise, according to the NIH.
According to the recommendation of a new consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association, newly diagnosed patients with diabetes should be treated with Merck KgaA's Glucophage (metformin) in conjunction with lifestyle modification unless the drug is contraindicated, according to the German drugmaker.
In response to a recent outbreak of rubella in India, nonprofit aid group AmeriCares is sending 55,000 doses of vaccine to help lower the risk of long-term disabilities caused by the virus, according to the organization.
Intercell AG announced that it has closed a worldwide non-exclusive agreement under which Wyeth has the right to use Intercell's fully synthetic novel adjuvant IC31 in various selected infectious disease vaccine programs.
Curis, Inc., a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, announced that it has formed a wholly foreign-owned enterprise form of subsidiary in Shanghai, China.
Chugai Pharmaceutical Co., Ltd. announced that it has entered into an agreement with Taisho Pharmaceutical Co., Ltd. to co-develop and co-market R484 (generic name: ibandronic acid), a bisphosphonate which Chugai is currently developing in Japan for the treatment of osteoporosis.
ALTANA AG announced that the Canadian regulatory authority Health Canada has granted marketing approval for Alvesco (ciclesonide), a lung-activated inhaled corticosteroid with novel release and distribution properties.
Bristol-Myers Squibb Company and Medivir AB announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen.
A new report released by RESULTS International says the World Bank is failing to provide African countries with the support to fight tuberculosis (TB) that it has effectively provided to other major endemic countries such as China, India and Russia.